FINNENCE ▪ THE WIRE FILE
THE WIRE · № 83200
SEC Filing■ Unclear/unknown
CRWD filed 4 on 2026-10-15
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Form 4 discloses insider transactions; direction depends on whether it was a buy or sale, not stated here.
Insider filing alone carries limited directional signal
CATALYST TO WATCH
Details of transaction size and direction
MAIN RISK
Could signal insider selling if a sale
FULL DISPATCH
CRWD (CIK 0001778564) filed a 4 on 2026-10-15.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTCrowdStrike · CRWD
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis — Almirall, S.A.2026-10-14 12:00 UTC
New Phase 3 trial: A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis — Almirall, S.A.2026-10-14 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome — Hoffmann-La Roche2026-10-14 12:00 UTC
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome — Hoffmann-La Roche2026-10-14 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) — Ultragenyx Pharmaceutical Inc2026-10-14 12:00 UTC
Phase 3 results posted: A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) — Ultragenyx Pharmaceutical Inc2026-10-14 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.